Viemed Healthcare, Inc.
NASDAQ•VMD
CEO: Mr. Casey Hoyt
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2019-08-09
Viemed Healthcare, Inc., together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment; and sells and rents HME devices. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.
Contact Information
Market Cap
$283.91M
P/E (TTM)
20.8
33.6
Dividend Yield
--
52W High
$8.62
52W Low
$5.93
52W Range
Rank40Top 42.0%
4.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$71.91M+23.98%
4-Quarter Trend
EPS
$0.09-9.82%
4-Quarter Trend
FCF
$10.73M+515.66%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Nine Month Revenue Growth Revenue totaled $194.1M for nine months, marking an 18.7% increase over prior period.
Net Income Significantly Rises Net income attributable to Viemed reached $9.3M, reflecting a strong 33.8% increase.
Lehan Acquisition Closed Completed Lehan acquisition for $28.7M consideration, recognizing $25.5M in resulting goodwill.
SG&A Efficiency Gains Selling, general and administrative expenses as percentage of revenue improved to 45.9%.
Risk Factors
Gross Margin Compression Noted Gross profit margin decreased to 57.4% due to changes in the revenue mix diversification.
Regulatory Coverage Uncertainty CMS finalized NCD for NIPPV, potentially affecting patient access and reimbursement across payer base.
Cash Position Decreased Cash and cash equivalents fell to $11.1M as of September 30, 2025, from $17.5M.
Supply Chain Cost Pressures Ongoing cost pressures from material, labor, and potential tariff escalation create operational uncertainty.
Outlook
Future Growth Strategy Expect growth through expansion of existing service areas and efficient launch into new territories.
Debt Repayment Anticipated Anticipate reduction in quarterly net interest expense for remainder of 2025 due to expected debt repayments.
Share Repurchase Completed Completed the 2025 Share Repurchase Program during the quarter, canceling 1.7M shares.
SG&A Improvement Expected Expect SG&A as percentage of revenue to continue improving through end of 2025 via efficiency initiatives.
Peer Comparison
Revenue (TTM)
INGN$347.03M
$311.51M
$254.79M
Gross Margin (Latest Quarter)
86.8%
75.8%
BWAY75.2%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| TCMD | $647.29M | 36.4 | 8.8% | 6.5% |
| NRC | $477.39M | 29.1 | 67.8% | 59.0% |
| BWAY | $458.11M | 74.3 | 9.5% | 6.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
5.8%
Steady Growth
4Q Net Income CAGR
-6.6%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Mar 9, 2026
EPS:$0.12
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 5, 2025|Revenue: $71.91M+24.0%|EPS: $0.09-9.8%MeetForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 6, 2025|Revenue: $63.06M+14.7%|EPS: $0.08+111.4%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 7, 2025|Revenue: $59.13M+16.9%|EPS: $0.07+75.0%BeatForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Mar 10, 2025|Revenue: $224.26M+22.5%|EPS: $0.29+7.4%BeatForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 6, 2024|Revenue: $58.00M+17.4%|EPS: $0.10+33.1%BeatForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 7, 2024|Revenue: $54.97M+26.9%|EPS: $0.04-38.6%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 6, 2024|Revenue: $50.59M+27.9%|EPS: $0.04+0.5%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Mar 6, 2024|Revenue: $183.01M+31.8%|EPS: $0.27+80.0%Beat